TNAT-101
Oncology (Colorectal Cancer, Triple-Negative Breast Cancer)
Pre-clinicalActive
Key Facts
Indication
Oncology (Colorectal Cancer, Triple-Negative Breast Cancer)
Phase
Pre-clinical
Status
Active
Company
About TNA Therapeutics
TNA Therapeutics is a private, pre-clinical stage company developing TNAT-101, a first-in-class oral inhibitor of the novel oncology target BCL3. The company's strategy centers on targeting cancer stem cells to not only induce tumor regression but also prevent metastasis and recurrence, addressing a significant gap in current cancer care. With $14 million invested, key patents, and GMP drug material manufactured, TNA is finalizing its IND package to initiate clinical trials. The company is pursuing a partnership-driven growth model, evidenced by collaborations in China and grant awards from UK entities.
View full company profile